BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is one of the most lethal malignancies with high mortality and short survival time.Computed tomography(CT)plays an important role in the diagnosis,staging and treatment...BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is one of the most lethal malignancies with high mortality and short survival time.Computed tomography(CT)plays an important role in the diagnosis,staging and treatment of pancreatic tumour.Pancreatic cancer generally shows a low enhancement pattern compared with normal pancreatic tissue.AIM To analyse whether preoperative enhanced CT could be used to predict postoperative overall survival in patients with PDAC.METHODS Sixty-seven patients with PDAC undergoing pancreatic resection were enrolled retrospectively.All patients underwent preoperative unenhanced and enhanced CT examination,the CT values of which were measured.The ratio of the preoperative CT value increase from the nonenhancement phase to the portal venous phase between pancreatic tumour and normal pancreatic tissue was calculated.The cut-off value of ratios was obtained by the receiver operating characteristic(ROC)curve of the tumour relative enhancement ratio(TRER),according to which patients were divided into low-and high-enhancement groups.Univariate and multivariate analyses were performed using Cox regression based on TRER grouping.Finally,the correlation between TRER and clinicopathological characteristics was analysed.RESULTS The area under the curve of the ROC curve was 0.768(P<0.05),and the cut-off value of the ROC curve was calculated as 0.7.TRER≤0.7 was defined as the low-enhancement group,and TRER>0.7 was defined as the high-enhancement group.According to the TRER grouping,the Kaplan-Meier survival curve analysis results showed that the median survival(10.0 mo)with TRER≤0.7 was significantly shorter than that(22.0 mo)with TRER>0.7(P<0.05).In the univariate and multivariate analyses,the prognosis of patients with TRER≤0.7 was significantly worse than that of patients with TRER>0.7(P<0.05).Our results demonstrated that patients in the low TRER group were more likely to have higher American Joint Committee on Cancer stage,tumour stage and lymph node stage(all P<0.05),and TRER was significantly negatively correlated with tumour size(P<0.05).CONCLUSION TRER≤0.7 in patients with PDAC may represent a tumour with higher clinical stage and result in a shorter overall survival.展开更多
BACKGROUND Genetic screening for breast cancer gene 1(BRCA)1/2 mutations can inform breast/ovarian/pancreatic cancer patients of suitable therapeutic interventions.Four to seven percent of pancreatic cancer patients h...BACKGROUND Genetic screening for breast cancer gene 1(BRCA)1/2 mutations can inform breast/ovarian/pancreatic cancer patients of suitable therapeutic interventions.Four to seven percent of pancreatic cancer patients have germline BRCA mutations.BRCA genes aid in DNA repair,especially homologous recombination,which impacts genomic stability and cancer cell growth.BRCA1 regulates the cell cycle,ubiquitination,and chromatin remodeling,whereas BRCA2 stimulates the immune response.They predict the efficacy of platinum chemotherapy or polymerase(PARP)inhibitors such as olaparib.AIM To determine the trends and future directions in the use of olaparib for pancreatic cancer treatment.METHODS To evaluate the trends in how olaparib works in pancreatic cancer,we performed a bibliometric analysis.One hundred and ninety-six related publications were accessed from the Web of Science Core Collection and were published between 2009 and 2022.The analytic parameters included publications,related citations,productive countries and institutes,influential authors,and keyword development.RESULTS This study visualizes and discusses the current research,including the present global trends and future directions in olaparib and pancreatic cancer.Overall,this study sheds light on optimizing the use of olaparib in pancreatic cancer treatment,Feng X et al.The use of olaparib in pancreatic cancer WJGO https://www.wjgnet.com 4490 November 15,2024 Volume 16 Issue 11 offering valuable guidance for researchers in this field.CONCLUSION Our findings identified trends in olaparib and pancreatic cancer,with China and the USA leading and with global cooperation tightening.O'Reilly EM's team and Memorial Sloan-Kettering had the highest output.The Journal of Clinical Oncology was the most cited journal.More PARP inhibitors are emerging,and combination therapy is suggested for future therapeutic trends.展开更多
Achieving the simultaneous enhancement of strength and ductility in laser powder bed fused (LPBF-ed) titanium (Ti) is challenging due to the complex, high-dimensional parameter space and interactions between parameter...Achieving the simultaneous enhancement of strength and ductility in laser powder bed fused (LPBF-ed) titanium (Ti) is challenging due to the complex, high-dimensional parameter space and interactions between parameters and powders. Herein, a hybrid intelligent framework for process parameter optimization of LPBF-ed Ti with improved ultimate tensile strength (UTS) and elongation (EL) was proposed. It combines the data augmentation method (AVG ± EC × SD), the multi-model fusion stacking ensemble learning model (GBDT-BPNN-XGBoost), the interpretable machine learning method and the non-dominated ranking genetic algorithm (NSGA-Ⅱ). The GBDT-BPNN-XGBoost outperforms single models in predicting UTS and EL across the accuracy, generalization ability and stability. The SHAP analysis reveals that laser power (P) is the most important feature affecting both UTS and EL, and it has a positive impact on them when P < 220 W. The UTS and EL of samples fabricated by the optimal process parameters were 718 ± 5 MPa and 27.9 % ± 0.1 %, respectively. The outstanding strength-ductility balance is attributable to the forward stresses in hard α'-martensite and back stresses in soft αm'-martensite induced by the strain gradients of hetero-microstructure. The back stresses strengthen the soft αm'-martensite, improving the overall UTS. The forward stresses stimulate the activation of dislocations in hard α'-martensite and the generation of 〈c + a〉 dislocations, allowing the plastic strain to occur in hard regions and enhancing the overall ductility. This work provides a feasible strategy for multi-objective optimization and valuable insights into tailoring the microstructure for improving mechanical properties.展开更多
基金Supported by the Medical Centre of Minimally Invasive Technology of Fujian Province,No.2017[171],and No.2017[4]Joint Funds for the Innovation of Science and Technology,Fujian Province,No.2017Y9059the United Fujian Provincial Health and Education Project for Tackling the Key Research,No.2019-WJ-07.
文摘BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is one of the most lethal malignancies with high mortality and short survival time.Computed tomography(CT)plays an important role in the diagnosis,staging and treatment of pancreatic tumour.Pancreatic cancer generally shows a low enhancement pattern compared with normal pancreatic tissue.AIM To analyse whether preoperative enhanced CT could be used to predict postoperative overall survival in patients with PDAC.METHODS Sixty-seven patients with PDAC undergoing pancreatic resection were enrolled retrospectively.All patients underwent preoperative unenhanced and enhanced CT examination,the CT values of which were measured.The ratio of the preoperative CT value increase from the nonenhancement phase to the portal venous phase between pancreatic tumour and normal pancreatic tissue was calculated.The cut-off value of ratios was obtained by the receiver operating characteristic(ROC)curve of the tumour relative enhancement ratio(TRER),according to which patients were divided into low-and high-enhancement groups.Univariate and multivariate analyses were performed using Cox regression based on TRER grouping.Finally,the correlation between TRER and clinicopathological characteristics was analysed.RESULTS The area under the curve of the ROC curve was 0.768(P<0.05),and the cut-off value of the ROC curve was calculated as 0.7.TRER≤0.7 was defined as the low-enhancement group,and TRER>0.7 was defined as the high-enhancement group.According to the TRER grouping,the Kaplan-Meier survival curve analysis results showed that the median survival(10.0 mo)with TRER≤0.7 was significantly shorter than that(22.0 mo)with TRER>0.7(P<0.05).In the univariate and multivariate analyses,the prognosis of patients with TRER≤0.7 was significantly worse than that of patients with TRER>0.7(P<0.05).Our results demonstrated that patients in the low TRER group were more likely to have higher American Joint Committee on Cancer stage,tumour stage and lymph node stage(all P<0.05),and TRER was significantly negatively correlated with tumour size(P<0.05).CONCLUSION TRER≤0.7 in patients with PDAC may represent a tumour with higher clinical stage and result in a shorter overall survival.
基金the Zhejiang Provincial Medical and Health Science and Technology Program,No.2024KY1109.
文摘BACKGROUND Genetic screening for breast cancer gene 1(BRCA)1/2 mutations can inform breast/ovarian/pancreatic cancer patients of suitable therapeutic interventions.Four to seven percent of pancreatic cancer patients have germline BRCA mutations.BRCA genes aid in DNA repair,especially homologous recombination,which impacts genomic stability and cancer cell growth.BRCA1 regulates the cell cycle,ubiquitination,and chromatin remodeling,whereas BRCA2 stimulates the immune response.They predict the efficacy of platinum chemotherapy or polymerase(PARP)inhibitors such as olaparib.AIM To determine the trends and future directions in the use of olaparib for pancreatic cancer treatment.METHODS To evaluate the trends in how olaparib works in pancreatic cancer,we performed a bibliometric analysis.One hundred and ninety-six related publications were accessed from the Web of Science Core Collection and were published between 2009 and 2022.The analytic parameters included publications,related citations,productive countries and institutes,influential authors,and keyword development.RESULTS This study visualizes and discusses the current research,including the present global trends and future directions in olaparib and pancreatic cancer.Overall,this study sheds light on optimizing the use of olaparib in pancreatic cancer treatment,Feng X et al.The use of olaparib in pancreatic cancer WJGO https://www.wjgnet.com 4490 November 15,2024 Volume 16 Issue 11 offering valuable guidance for researchers in this field.CONCLUSION Our findings identified trends in olaparib and pancreatic cancer,with China and the USA leading and with global cooperation tightening.O'Reilly EM's team and Memorial Sloan-Kettering had the highest output.The Journal of Clinical Oncology was the most cited journal.More PARP inhibitors are emerging,and combination therapy is suggested for future therapeutic trends.
基金supported by the National Natural Sci-ence Foundation of China(Nos.52274359 and 52304379)the China National Postdoctoral Program for Innovative Talents(No.BX20220034)+2 种基金the China Postdoctoral Science Foundation(No.2022M720403)the AECC University Research Cooperation Project(No.HFZL2021CXY021)the Interdisciplinary Research Project for Young Teachers of USTB(Fundamental Research Funds for the Central Universities)(No.FRF-IDRY-23-025).
文摘Achieving the simultaneous enhancement of strength and ductility in laser powder bed fused (LPBF-ed) titanium (Ti) is challenging due to the complex, high-dimensional parameter space and interactions between parameters and powders. Herein, a hybrid intelligent framework for process parameter optimization of LPBF-ed Ti with improved ultimate tensile strength (UTS) and elongation (EL) was proposed. It combines the data augmentation method (AVG ± EC × SD), the multi-model fusion stacking ensemble learning model (GBDT-BPNN-XGBoost), the interpretable machine learning method and the non-dominated ranking genetic algorithm (NSGA-Ⅱ). The GBDT-BPNN-XGBoost outperforms single models in predicting UTS and EL across the accuracy, generalization ability and stability. The SHAP analysis reveals that laser power (P) is the most important feature affecting both UTS and EL, and it has a positive impact on them when P < 220 W. The UTS and EL of samples fabricated by the optimal process parameters were 718 ± 5 MPa and 27.9 % ± 0.1 %, respectively. The outstanding strength-ductility balance is attributable to the forward stresses in hard α'-martensite and back stresses in soft αm'-martensite induced by the strain gradients of hetero-microstructure. The back stresses strengthen the soft αm'-martensite, improving the overall UTS. The forward stresses stimulate the activation of dislocations in hard α'-martensite and the generation of 〈c + a〉 dislocations, allowing the plastic strain to occur in hard regions and enhancing the overall ductility. This work provides a feasible strategy for multi-objective optimization and valuable insights into tailoring the microstructure for improving mechanical properties.
